PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20333699-0	2010	5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.	Azacitidine	0-13	androgen receptor	Homo sapiens	88-105	
33195208-3	2020	In the current study, treatment of 5"-Aza or MS-275/enzalutamide induced poly (ADP-ribose) polymerase (PARP) cleavage and p-H2A.X in CaP cells with an increase of maspin expression but a decrease of AR.	Azacitidine	35-41	androgen receptor	Homo sapiens	104-106	
20338164-5	2010	Results of 5-Aza-2"-deoxycytidine (5-Aza) experiments, methylation-specific PCR, and sodium bisulfite-direct DNA sequencing revealed that the AR promoter is hypermethylated in metastatic M12, but not in benign P69, cells.	Azacitidine	11-16	androgen receptor	Homo sapiens	142-144	
20338164-7	2010	We show, however, that 5-Aza treatment, which caused demethylation of the AR promoter, led to a significant increase in IGF1R mRNA levels, whereas addition of the AR inhibitor flutamide decreased the IGF1R mRNA levels to basal values measured prior to the 5-Aza treatment.	Azacitidine	23-28	androgen receptor	Homo sapiens	74-76	
20338164-7	2010	We show, however, that 5-Aza treatment, which caused demethylation of the AR promoter, led to a significant increase in IGF1R mRNA levels, whereas addition of the AR inhibitor flutamide decreased the IGF1R mRNA levels to basal values measured prior to the 5-Aza treatment.	Azacitidine	256-261	androgen receptor	Homo sapiens	74-76